Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

906.18 3.28 +0.36%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100

Regeneron Pharmaceuticals, Inc. (REGN) Net margin

Alert me on Net margin

Regeneron Pharmaceuticals, Inc.'s net margin over the twelve months to 30 September 2026 was 28.5%, down 2.9 percentage points from fiscal 2025 (31.4%). Over the past ten years it has ranged from 15.5% (fiscal 2015) to 50.3% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 31.4% 0.34
FY2024 31.1% 0.93
FY2023 30.1% (5.50)
FY2022 35.6% (14.61)
FY2021 50.3% 8.90
FY2020 41.4% 9.09
FY2019 32.3% (15.24)
FY2018 47.5% 27.09
FY2017 20.4% 1.99
FY2016 18.4% 2.92

Quarterly newest first

Period Net margin Change (points)
Sep 2026 38.1% 7.86
Jun 2026 30.2% 10.06
Mar 2026 20.2% (1.57)
Dec 2025 21.7% (17.15)
43 more quarters

Against its own ten years

Low 15.5% High 50.3%
Ten-year median 31.4%
Current reading's percentile 30

Net margin against peers

Company Net margin
ARGX argenex SE compare 31.7%
VRTX Vertex Pharmaceuticals Incorporated compare 30.7%
REGN Regeneron Pharmaceuticals, Inc. 28.5%
GMAB Genmab A/S Sponsored ADR compare 19.1%
ONC BeOne Medicines Ltd. - Sponsored ADR compare 13.9%
RPRX Royalty Pharma PLC compare 0.00%
MRNA Moderna, Inc. compare −141.4%
RVMD Revolution Medicines, Inc. compare −894.4%
ROIV Roivant Sciences Ltd. compare −3,535.0%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 1.06%

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on REGN